J1299 HCPCS code: Injection, eculizumab, 2 mg
J1299 is the HCPCS Level II code for injection, eculizumab, 2 mg. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 600 per day on DME suppliers.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2025-04-01 |
| Last action effective | 2025-04-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 600 | Prescribing Information |
| outpatient hospital claims | 600 | Prescribing Information |
| practitioner claims | 600 | Prescribing Information |
Medicare policy articles for this code
- A54548: Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI®-eculizumab-aagh, and BKEMV™-eculizumab-aeeb (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (18 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| D59.31 | Infection-associated hemolytic-uremic syndrome | 1 |
| D59.32 | Hereditary hemolytic-uremic syndrome | 1 |
| D59.39 | Other hemolytic-uremic syndrome | 1 |
| D59.5 | Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] | 1 |
| G36.0 | Neuromyelitis optica [Devic] | 1 |
| G70.00 | Myasthenia gravis without (acute) exacerbation | 1 |
| G70.01 | Myasthenia gravis with (acute) exacerbation | 1 |
| N00.6 | Acute nephritic syndrome with dense deposit disease | 1 |
| N00.B1 | Acute nephritic syndrome with idiopathic immune membranoproliferative glomerulonephritis (IC-MPGN) | 1 |
| N00.B2 | Acute nephritic syndrome with secondary immune complex membranoproliferative glomerulonephritis (IC-MPGN) | 1 |
Showing 10 of 18. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J1299
- April 2025: Code appears in this HCPCS release
- 2025-04-01: J1299 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1299?
J1299 is the HCPCS Level II code for injection, eculizumab, 2 mg. Short descriptor: "Inj, eculizumab, 2 mg".
Does Medicare cover J1299?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J1299?
Medicare policy articles that cite J1299 list 18 covered ICD-10-CM diagnosis codes across 1 article. The most cited include D59.31 (Infection-associated hemolytic-uremic syndrome), D59.32 (Hereditary hemolytic-uremic syndrome), D59.39 (Other hemolytic-uremic syndrome). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J1299 can be billed per day?
600 on DME suppliers; 600 on outpatient hospital claims; 600 on practitioner claims (NCCI medically unlikely edits).
Related J12 codes
- J1200 — Injection, diphenhydramine hcl, up to 50 mg
- J1201 — Injection, cetirizine hydrochloride, 0.5 mg
- J1202 — Miglustat, oral, 65 mg
- J1203 — Injection, cipaglucosidase alfa-atga, 5 mg
- J1205 — Injection, chlorothiazide sodium, per 500 mg
- J1212 — Injection, dmso, dimethyl sulfoxide, 50%, 50 ml
- J1230 — Injection, methadone hcl, up to 10 mg
- J1240 — Injection, dimenhydrinate, up to 50 mg
- J1245 — Injection, dipyridamole, per 10 mg
- J1250 — Injection, dobutamine hydrochloride, per 250 mg
- J1260 — Injection, dolasetron mesylate, 10 mg
- J1265 — Injection, dopamine hcl, 40 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1299
- Watch J1299 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1299
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.